Chalcone Compound for Atherosclerosis Treatment via PPARγ Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis, including antilipemic and antithrombotic agents, often come with significant side effects, necessitating the development of new drugs that can effectively prevent and treat the condition without these adverse reactions.
Innovation Solution
Synthesis of chalcone compounds, particularly one with ortho-hydroxy in ring A and para-methoxy in ring B, which inhibit human aortic smooth muscle cell proliferation induced by oxidized-LDL, exhibit anti-inflammatory properties, and show synergism with PPARγ ligands to regulate key signaling pathways and expressions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antilipemic agents or antithrombotic agents are used to treat atherosclerosis, then the condition can be treated, but significant side effects occur
Solution Approach 1:
The patent changes the chemical structure parameters by synthesizing chalcone compounds with specific substituent patterns (ortho-hydroxy in ring A and para-methoxy in ring B) to achieve effective atherosclerosis treatment while reducing side effects. This structural parameter optimization allows the compound to interact with cellular pathways differently than conventional drugs, achieving therapeutic effects with reduced toxicity.
Solution Approach 2:
The invention creates a composite pharmacological approach by combining chalcone compound structures with multiple biological activities (inhibiting smooth muscle cell proliferation, reducing inflammation, regulating lipid metabolism) to achieve comprehensive atherosclerosis treatment with reduced side effects compared to single-mechanism conventional drugs.
2Object-affected harmful factors
If chalcone compounds with specific structures are synthesized to reduce side effects, then side effects are reduced, but the complexity of compound synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the chalcone molecule into two distinct rings (ring A and ring B) with specific substituent patterns. This segmentation allows independent optimization of each ring's properties: ring A with ortho-hydroxy substitution for biological activity and ring B with para-methoxy substitution for stability and reduced side effects, making the synthesis process more manageable.
Solution Approach 2:
The invention applies local quality by placing specific functional groups at specific locations within the chalcone structure. The ortho-hydroxy group in ring A and para-methoxy group in ring B are positioned to interact with specific cellular targets, achieving localized biological effects that reduce side effects while maintaining therapeutic efficacy.
Data Source
AI summary
Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).